Failure of equipment to perform in the manner for which it was designed so as to assure compliance with the official requirements prescribed in 21 CFR 606.
Inspection Record
Biomat USA, Inc. — FDA 483 Findings
Inspectors Emily B CamireThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Written standard operating procedures including all steps to be followed in the collection of blood and blood components for further manufacturing purposes were not always established.
Records are not concurrently maintained with the performance of each significant step in the collection of each unit of blood and blood components so that all steps can be clearly traced.
Failure to perform a thorough investigation of an unexplained discrepancy anda failure of a lot or unit to meet any of its specifications.
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.